Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 18/20 | 0.56 |
| ▸ | TPH2 | Q8IWU9 | 10/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GRB2 | P62993 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307732 | 0.86 | TPH1 (0.59) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL3682569 | 0.86 | TPH1 (0.59) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL309653 | 0.81 | TPH1 (0.79) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL20274832 | 0.81 | TPH1 (0.79) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL612769 | 0.80 | TPH1 (0.78) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL612770 | 0.80 | TPH1 (0.78) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL4535049 | 0.80 | TPH1 (0.78) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL871416 | 0.76 | TPH1 (0.74) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL871415 | 0.76 | TPH1 (0.74) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL31369930 | 0.75 | SLC13A5 (0.54) | TPH1TPH2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386547-B1 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-8629156-B2 | Tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | LEXICON PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8410121-B2 | Methods of treating pulmonary hypertension | LEXICON PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2533778-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | Lexicon Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120316171-A1 | Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer | LEXICON PHARMACEUTICALS, INC. | 2012-12-13 | — | — | US | disclosed |
| EP-1984344-B1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2496231-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF CANCER | Lexicon Pharmaceuticals, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120157484-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS | TERSERA THERAPEUTICS LLC | 2012-06-21 | — | — | US | disclosed |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2009014972-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009009561-A1 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION AND RELATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090005382-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | TERSERA THERAPEUTICS LLC | 2009-01-01 | — | — | US | disclosed |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2009002964-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002970-A1 | COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1984344-A2 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2007089335-A2 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICAL INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | TPH1, TPH2, PTGIS | TPH1 1/4885TPH2 2/4885F2 1046/4885 |
| US-20120316171-A1 | Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885F2 4527/4885 |
| US-20120157484-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885F2 2900/4885 |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | AADAT, HNMT, TPH1 | TPH1 3/4885TPH2 4/4885F2 808/4885 |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | TPH1, TPH2, IDO1 | TPH1 1/4885TPH2 2/4885F2 4049/4885 |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885F2 2242/4885 |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885F2 1080/4885 |
| US-20090005382-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, MAOB | TPH1 1/4885TPH2 2/4885F2 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.